BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NT-175 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NT-175\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05877599-2645@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:NT-175: Phase 1 readout est. (NCT05877599)
DESCRIPTION:NT-175\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of NT-175 in Adult Participants With Advanced Malignancies That Are Positi
 ve for HLA-A*02:01 and the TP53 R175H Mutation\nEstimated primary completi
 on: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nt-
 175#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05877599
URL:https://assetmemo.bio/drug/nt-175#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
